The rising interest in effective weight management has led to considerable investigation into cutting-edge treatments. Currently, Retatrutide, a combined -action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor stimulator, has shown positive results in clinical trials, implying potential for substantia